JPH0686446B2 - ４ｈ−１−ベンゾピラン−４−オン誘導体およびその製法 - Google Patents

４ｈ−１−ベンゾピラン−４−オン誘導体およびその製法

Info

Publication number
JPH0686446B2
JPH0686446B2 JP62087252A JP8725287A JPH0686446B2 JP H0686446 B2 JPH0686446 B2 JP H0686446B2 JP 62087252 A JP62087252 A JP 62087252A JP 8725287 A JP8725287 A JP 8725287A JP H0686446 B2 JPH0686446 B2 JP H0686446B2
Authority
JP
Japan
Prior art keywords
alkyl
formula
compound
hydrogen
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP62087252A
Other languages
English (en)
Japanese (ja)
Other versions
JPS62242680A (ja
Inventor
サンバ・ラクスミナラヤン・カツテイジ
ラムチヤンドラ・ガナパテイ・ナイク
アフタブ・ダウツドブハイ・ラクダワラ
アリフセイン・ノーマンブハイ・ドハドワラ
リヒアルト・ヘルムート・ルツプ
ノエル・ジヨン・デスーザ
Original Assignee
ヘキスト・アクチエンゲゼルシヤフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヘキスト・アクチエンゲゼルシヤフト filed Critical ヘキスト・アクチエンゲゼルシヤフト
Publication of JPS62242680A publication Critical patent/JPS62242680A/ja
Publication of JPH0686446B2 publication Critical patent/JPH0686446B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP62087252A 1986-04-11 1987-04-10 ４ｈ−１−ベンゾピラン−４−オン誘導体およびその製法 Expired - Lifetime JPH0686446B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19863612337 DE3612337A1 (de) 1986-04-11 1986-04-11 4h-1-benzopyran-4-on-derivate, ein verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3612337.4 1986-04-11

Publications (2)

Publication Number Publication Date
JPS62242680A JPS62242680A (ja) 1987-10-23
JPH0686446B2 true JPH0686446B2 (ja) 1994-11-02

Family

ID=6298535

Family Applications (1)

Application Number Title Priority Date Filing Date
JP62087252A Expired - Lifetime JPH0686446B2 (ja) 1986-04-11 1987-04-10 ４ｈ−１−ベンゾピラン−４−オン誘導体およびその製法

Country Status (15)

Country Link
US (1) US4900727A (en:Method)
EP (1) EP0241003B1 (en:Method)
JP (1) JPH0686446B2 (en:Method)
KR (1) KR950009861B1 (en:Method)
AT (2) ATE95519T1 (en:Method)
AU (1) AU602891B2 (en:Method)
CA (1) CA1332238C (en:Method)
DE (2) DE3612337A1 (en:Method)
DK (1) DK169760B1 (en:Method)
ES (1) ES2060582T3 (en:Method)
IE (1) IE62244B1 (en:Method)
IL (1) IL82149A (en:Method)
IN (1) IN164232B (en:Method)
PT (1) PT84654B (en:Method)
ZA (1) ZA872555B (en:Method)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
DE3836676A1 (de) * 1988-10-28 1990-05-03 Hoechst Ag Die verwendung von 4h-1-benzopyran-4-on-derivaten, neue 4h-1-benzopyran-4-on-derivate und diese enthaltende arzneimittel
US5278174A (en) * 1990-06-04 1994-01-11 Scios Nova, Inc. Sigma binding site agents
EP0508347A1 (en) * 1991-04-10 1992-10-14 Hoechst Aktiengesellschaft 5,7-Dihydroxy-2-methyl-8-[4-(3-hydroxy-1-(1-propyl)) piperidinyl]-4H-1-benzopyran-4-one, its preparation and its use
GB9604709D0 (en) * 1996-03-05 1996-05-01 Imperial College A compound
US6476011B1 (en) 1991-08-28 2002-11-05 Sterix Limited Methods for introducing an estrogenic compound
US6903084B2 (en) 1991-08-28 2005-06-07 Sterix Limited Steroid sulphatase inhibitors
US6011024A (en) 1991-08-28 2000-01-04 Imperial College Of Science Technology & Medicine Steroid sulphatase inhibitors
SK280617B6 (sk) * 1992-01-16 2000-05-16 Hoechst Aktiengesellschaft Arylcykloalkylové deriváty, spôsob ich prípravy, f
US5733920A (en) * 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US6506792B1 (en) 1997-03-04 2003-01-14 Sterix Limited Compounds that inhibit oestrone sulphatase and/or aromatase and methods for making and using
US20060241173A1 (en) * 1996-02-16 2006-10-26 Sterix Ltd. Compound
US6087366A (en) * 1996-03-07 2000-07-11 The Trustees Of Columbia University In The City Of New York Use of flavopiridol or a pharmaceutically acceptable salt thereof for inhibiting cell damage or cell death
US5849733A (en) * 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
US5908934A (en) * 1996-09-26 1999-06-01 Bristol-Myers Squibb Company Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs
DE19802449A1 (de) * 1998-01-23 1999-07-29 Hoechst Marion Roussel De Gmbh Verfahren zur Herstellung von (-)cis-3-Hydroxy-1-methyl-4-(2,4,6-trimethoxypyhenyl)-piperidin
GB9807779D0 (en) * 1998-04-09 1998-06-10 Ciba Geigy Ag Organic compounds
US6399633B1 (en) * 1999-02-01 2002-06-04 Aventis Pharmaceuticals Inc. Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
DE19959546A1 (de) * 1999-12-09 2001-06-21 Rhone Poulenc Rorer Gmbh Pharmazeutische Zubereitung zur Behandlung von Tumorerkrankungen
US7335650B2 (en) 2000-01-14 2008-02-26 Sterix Limited Composition
US6821990B2 (en) * 2000-01-18 2004-11-23 Aventis Pharma Deutschland Gmbh Ethanol solvate of (-)-cis-2-(2-chlorophenyl)-5, 7-dihydroxy-8 [4R-(3S-hydroxy-1-M ethyl) piperidinyl]-4H-1-benzopyran-4-one
US6576647B2 (en) 2000-01-18 2003-06-10 Aventis Pharmaceuticals Inc. Pseudopolymorph of (—)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4R-(3S-hydroxy -1-methyl)piperidinyl]-4H-1-benzopyran-4-one
HUP0204126A3 (en) * 2000-01-18 2006-02-28 Aventis Pharma Inc Pseudopolymorph of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one, process for their preparation and pharmaceutical compositions containing them
JP2003520798A (ja) * 2000-01-18 2003-07-08 アベンテイス・フアーマシユーチカルズ・インコーポレーテツド （−）−シス−２−（２−クロロフェニル）−５，７−ジヒドロキシ−８［４ｒ−（３ｓ−ヒドロキシ−１−メチル）ピペリジニル］−４ｈ−１−ベンゾピラン−４−オンのエタノール溶媒化合物
FR2805538B1 (fr) * 2000-02-29 2006-08-04 Hoechst Marion Roussel Inc Nouveaux derives de flavones, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
KR100423899B1 (ko) 2000-05-10 2004-03-24 주식회사 엘지생명과학 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸
CN100381437C (zh) 2002-04-17 2008-04-16 赛特凯恩蒂克公司 化合物、组合物和方法
US7271193B2 (en) * 2002-07-08 2007-09-18 Nicholas Piramal India, Ltd. Inhibitors of cyclin-dependent kinases and their use
US7884127B2 (en) * 2002-07-08 2011-02-08 Pirimal Life Sciences Ltd. Inhibitors of cyclin dependent kinases and their use
US7915301B2 (en) 2002-07-08 2011-03-29 Piramal Life Science Limited Inhibitors of cyclin dependent kinases and their use
EP1539727B1 (en) * 2002-07-17 2009-02-18 Cytokinetics, Inc. Compounds, compositions, and methods for treating cellular proliferative diseases
JP2005539062A (ja) * 2002-09-13 2005-12-22 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
WO2005042697A2 (en) * 2003-10-06 2005-05-12 Cytokinetics, Inc. Compounds, compositions and methods
MXPA06006651A (es) * 2003-12-09 2006-08-11 Gov Health & Human Serv Metodos para suprimir una respuesta inmune o un tratamiento para un trastorno proliferativo.
WO2005058341A2 (en) * 2003-12-11 2005-06-30 Theravance, Inc. Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
ES2552338T3 (es) 2005-01-21 2015-11-27 Astex Therapeutics Limited Compuestos farmacéuticos
WO2007148158A1 (en) 2006-06-21 2007-12-27 Piramal Life Sciences Limited Enantiomerically pure flavone derivatives for the treatment of poliferative disorders and processes for their preparation
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
TWI461194B (zh) 2009-05-05 2014-11-21 Piramal Entpr Ltd 吡咯啶取代黃酮作為輻射致敏劑
EP2538941A1 (en) 2010-02-26 2013-01-02 Piramal Enterprises Limited Pyrrolidine substituted flavones for the treatment of inflammatory disorders
WO2011159726A2 (en) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogramming of cells to a new fate
TW201300105A (zh) 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物
CA2909280C (en) 2013-04-10 2021-03-30 Council Of Scientific & Industrial Research Chromone alkaloid dysoline for the treatment of cancer and inflammatory disorders
EP2986605B1 (en) 2013-04-17 2017-11-15 Council of Scientific and Industrial Research Rohitukine analogs as cyclin-dependent kinase inhibitors and a process for the preparation thereof
TWI680760B (zh) 2013-07-12 2020-01-01 印度商皮拉馬爾企業有限公司 治療黑色素瘤的藥物組合
US20170306046A1 (en) 2014-11-12 2017-10-26 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
EP3611506B1 (en) 2015-04-20 2021-11-17 Sumitomo Dainippon Pharma Oncology, Inc. Predicting response to alvocidib by mitochondrial profiling
AU2016264212B2 (en) 2015-05-18 2020-10-22 Sumitomo Pharma Oncology, Inc. Alvocidib prodrugs having increased bioavailability
RU2759963C2 (ru) 2015-08-03 2021-11-19 Сумитомо Даиниппон Фарма Онколоджи, Инк. Комбинированные терапии для лечения рака
IL302822A (en) 2015-11-12 2023-07-01 Seagen Inc Glycan-interacting compounds and methods of use
US11401330B2 (en) 2016-11-17 2022-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
KR20190099260A (ko) 2016-12-19 2019-08-26 톨레로 파마수티컬스, 인크. 프로파일링 펩티드 및 감도 프로파일링을 위한 방법
AU2018226824A1 (en) 2017-03-03 2019-09-19 Seagen Inc. Glycan-interacting compounds and methods of use
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
KR20210099066A (ko) 2018-12-04 2021-08-11 스미토모 다이니폰 파마 온콜로지, 인크. 암의 치료를 위한 작용제로서 사용하기 위한 cdk9 억제제 및 그의 다형체
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
WO2020213714A1 (ja) * 2019-04-18 2020-10-22 大日本住友製薬株式会社 シス－（－）－フロシノピペリドールの製造方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1223690A (en) * 1967-10-17 1971-03-03 Fisons Pharmaceuticals Ltd Substituted chromon-2-carboxylic acids
DE2731566A1 (de) * 1977-07-13 1979-02-01 Bayer Ag Verfahren zur herstellung von neuen chromon-derivaten, sowie ihre verwendung als pflanzenschutzmittel
GB2101115A (en) * 1980-10-23 1983-01-12 Pfizer Ltd Thromboxane synthetase inhibitors
DE3311005A1 (de) * 1983-03-25 1984-09-27 Bayer Ag, 5090 Leverkusen Chromon- und thiochromonsubstituierte 1,4-dihydropyridinderivate, mehrere verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
DE3329186A1 (de) * 1983-08-12 1985-02-21 Hoechst Ag, 6230 Frankfurt Chromonalkaloid, verfahren zu seiner isolierung aus dysoxylum binectariferum, und seine verwendung als arzneimittel
DE3445852A1 (de) * 1984-12-15 1986-06-19 Bayer Ag, 5090 Leverkusen Dihydropyridin-carbonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln

Also Published As

Publication number Publication date
IL82149A0 (en) 1987-10-30
DK185287A (da) 1987-10-12
DE3787661D1 (de) 1993-11-11
IL82149A (en) 1994-01-25
PT84654A (de) 1987-05-01
EP0241003B1 (de) 1993-10-06
PT84654B (pt) 1989-12-29
HK1006021A1 (en) 1999-02-05
ZA872555B (en) 1987-11-25
AU602891B2 (en) 1990-11-01
DE3612337A1 (de) 1987-10-15
KR870010045A (ko) 1987-11-30
KR950009861B1 (en) 1995-08-29
US4900727A (en) 1990-02-13
JPS62242680A (ja) 1987-10-23
IE870941L (en) 1987-10-11
ATE95519T1 (de) 1993-10-15
CA1332238C (en) 1994-10-04
IE62244B1 (en) 1995-01-11
DK185287D0 (da) 1987-04-10
AT389875B (de) 1990-02-12
IN164232B (en:Method) 1989-02-04
DK169760B1 (da) 1995-02-20
ES2060582T3 (es) 1994-12-01
ATA260587A (de) 1989-07-15
EP0241003A3 (en) 1988-10-12
EP0241003A2 (de) 1987-10-14
AU7139787A (en) 1987-10-15

Similar Documents

Publication Publication Date Title
JPH0686446B2 (ja) ４ｈ−１−ベンゾピラン−４−オン誘導体およびその製法
EP1077940B1 (en) 4-phenylpiperidines for the treatment of pruritic dermatoses
JPH0272173A (ja) ヘテロ環化合物、その製造法およびその医薬への応用
US4711899A (en) 2-(4-benzoyl-1-piperidyl)-1-phenylalkanol derivatives
US5212182A (en) Substituted quinolinyl- and naphthalenylbenzamides or benzylamines and related compounds useful as analgesics
JPS6112910B2 (en:Method)
US5684046A (en) Hydrogenated naphthalenes and related LTB4 antagonists
NO803453L (no) Fremgangsmaate ved fremstilling av piperidylbenzimidazolonderivater
US4420480A (en) Hexahydronaphth[1,2-b]-1,4-oxazines
JPS6277380A (ja) 複素環式化合物の製造法
JPH06500076A (ja) ピペリジン化合物、その合成およびその使用方法
US4425353A (en) Analgesic 5-oxygenated-6,7-benzomorphan derivatives
CA2072520A1 (en) 2-(1-piperidyl) ethanol derivatives, their preparation and their therapeutic application
EP1072596A2 (en) 4-arylpiperidine derivatives for the treatment of pruritus
Sanfilippo et al. Thiophene systems. 14. Synthesis and antihypertensive activity of novel 7-(cyclic amido)-6-hydroxythieno [3, 2-b] pyrans and related compounds as new potassium channel activators
US5075317A (en) Spirofurane derivatives
HU185432B (en) Process for producing indene derivatives
JPS59176255A (ja) ２−〔２−ヒドロキシ−４−（置換）フエニル〕ピペリジン化合物
NL8105623A (nl) Nieuwe hydroxyfenyltetrahydropyridineverbindingen, hun zouten, werkwijze voor hun bereiding en tussenprodukten bij de bereiding, toepassing als geneesmiddelen en samenstelling die zij bevatten.
US4443453A (en) Quinoline derivatives, pharmaceutical compositions containing such compounds, and methods for treating cardiovascular conditions with them
EP0745591B1 (en) Indanylpiperidines as melatonergic agents
EP0035819A1 (en) Quinoline derivatives, pharmaceutical compositions containing such compounds, and methods for the preparation of these compounds
FR2661178A1 (fr) Derives de [(tetrahydro-1,2,3,4 isoquinoleinyl-2)methyl]-4 piperidinecarboxylates-1 d'alkyle, leur preparation et leur application en therapeutique.
SE460418B (sv) Derivat av 3-azabicyklo /3.3.1/ nonan-9-ol, foerfarande foer framstaellning av detta, farmaceutiska komposition och en mellanprodukt
KR820001356B1 (ko) 벤조[c] 퀴놀린의 제조방법

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term
FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20071102

Year of fee payment: 13